Hexarelin

Hexarelin
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	140703-51-1
PubChem	5486806
DrugBank
ChemSpider	4589241
KEGG	D06092

Hexarelin is a synthetic growth hormone secretagogue that belongs to the class of peptide hormones. It is a hexapeptide that stimulates the release of growth hormone (GH) from the pituitary gland.

Mechanism of Action

Hexarelin acts by binding to the growth hormone secretagogue receptor (GHSR) in the hypothalamus and pituitary gland. This binding stimulates the secretion of growth hormone, which plays a crucial role in growth, metabolism, and body composition.

Clinical Uses

Hexarelin has been studied for its potential use in treating growth hormone deficiency and other conditions related to low levels of growth hormone. It may also have applications in cardiovascular disease due to its effects on cardiac function.

Pharmacokinetics

Hexarelin is administered via subcutaneous injection. It has a rapid onset of action, with peak growth hormone levels occurring within 30 minutes of administration. The half-life of hexarelin is approximately 55 minutes.

Side Effects

Common side effects of hexarelin include injection site reactions, headache, and nausea. Long-term use may lead to desensitization of the growth hormone secretagogue receptor, reducing its effectiveness.

Research

Research on hexarelin has shown potential benefits in muscle growth, fat loss, and cardioprotection. However, more studies are needed to fully understand its effects and safety profile.

See Also

• Growth hormone releasing peptide
• Peptide therapy
• Endocrinology

External Links

• [PubChem Entry for Hexarelin](https://pubchem.ncbi.nlm.nih.gov/compound/5486806)
• [ChEMBL Entry for Hexarelin](https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1189645)